Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Common Equity (2020 - 2025)

NeuroPace has reported Common Equity over the past 6 years, most recently at $19.0 million for Q4 2025.

  • Quarterly results put Common Equity at $19.0 million for Q4 2025, up 137.5% from a year ago — trailing twelve months through Dec 2025 was $19.0 million (up 137.5% YoY), and the annual figure for FY2025 was $19.0 million, up 137.5%.
  • Common Equity for Q4 2025 was $19.0 million at NeuroPace, up from $18.5 million in the prior quarter.
  • Over the last five years, Common Equity for NPCE hit a ceiling of $88.7 million in Q2 2021 and a floor of -$156.4 million in Q1 2021.
  • Median Common Equity over the past 5 years was $20.9 million (2023), compared with a mean of $24.5 million.
  • Biggest five-year swings in Common Equity: surged 161.45% in 2021 and later tumbled 62.31% in 2023.
  • NeuroPace's Common Equity stood at $73.5 million in 2021, then crashed by 52.69% to $34.8 million in 2022, then plummeted by 40.61% to $20.7 million in 2023, then plummeted by 61.2% to $8.0 million in 2024, then skyrocketed by 137.5% to $19.0 million in 2025.
  • The last three reported values for Common Equity were $19.0 million (Q4 2025), $18.5 million (Q3 2025), and $19.4 million (Q2 2025) per Business Quant data.